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Introduction
Gene mosaicism describes an individual who has devel-
oped from a single zygote and has two or more cell types
with distinct genotypes. Three major types of mosaicism
have been described and are referred as gonadal, somatic
and gonosomic mosaicism. They mainly differ on the
body distribution of the somatic mutation and in their
clinical consequences. The recent use of next-generation
sequencing technologies is revealing the relevant role of
gene mosaicism in various diseases other than cancer,
including monogenic autoinflammatory diseases such as
cryopyrinopathies and STING-associated vasculopathy
with onset in infancy [1-3].
Objectives
To describe the first known cases of somatic and gono-
somic NOD2 mosaicism in Blau syndrome (BS).
Patients and methods
Genomic DNA was extracted from hematopoietic and
non-hematopoietic cell types. NOD2 analyses were per-
formed by both Sanger sequencing and targeted deep
sequencing (TDS).
Results
The first patient is a 17-year-old Moroccan girl who pre-
sented with bilateral red eye at the age of 3 years. Severe
panuveitis, erythematous rash and oligoarthritis were
observed during the following years. Sanger sequencing
did not clearly detect any disease-causing NOD2 mutation.
However, a careful analysis of Sanger chromatograms
revealed a potential c.1001G>A transition that might
cause the appearance of the well-known p.Arg334Gln
NOD2 mutation. TDS confirmed the presence of somatic
NOD2 mosaicism by means of the detection of the
somatic p.Arg334Gln mutation in hematopoietic and
non-hematopoietic tissues with variable frequencies
(4.9-11.0%).
The second patient is a 37-year-old Malaysian male
suffering from skin rash and bilateral uveitis since the age
of 22 years. He has two affected daughters, aged 4- and
2-year-old, with the classical BS triad (skin rash, polyar-
thritis and uveitis). Sanger NOD2 sequencing revealed
the germline p.Arg334Gln mutation in both daughters,
and unexpectedly its absence in the father. Further analy-
sis of father’s Sanger chromatograms suggested the pre-
sence of the p.Arg334Gln mutation as a potential
somatic mutation. TDS confirmed the presence of gono-
somic NOD2 mosaicism in the father by means of the
detection of the somatic p.Arg334Gln mutation in differ-
ent tissues with different allele frequencies (0.9-12.9%).
Conclusions
We describe for the first time the involvement of NOD2
mosaicism in BS pathogenesis by using the novel TDS
technology. Our findings clearly support that gene
mosaicism might have a relevant role in either “mutation-
negative” BS patients or in parents of an affected child
with an apparent de novo germline mutation.
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